Cancer Prevention Pharmaceuticals, Inc.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

Eflornithine plus Sulindac · Oncology
Eflornithine inhibits polyamine synthesis while sulindac acts as a non-selective NSAID to reduce inflammation and promote apoptosis, together targeting colorectal cancer prevention.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Cancer Prevention Pharmaceuticals, Inc. portfolio CI brief
Cancer Prevention Pharmaceuticals, Inc. pipeline updates RSS